CoChat

Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation With Hypertrophic Cardiomyopathy

Open access
Jung, Hyunjean, Yang, Pil-Sung, Jang, Eunsun, Yu, Hee Tae, Kim, Tae-Hoon, Uhm, Jae-Sun, Kim, Jong-Youn, Pak, Hui-Nam, Lee, Moon-Hyoung, Joung, Boyoung, Lip, Gregory Y.H. · 2019 · Chest
Cited by 70

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Chronic anticoagulation is recommended in patients with hypertrophic cardiomyopathy (HCM) and atrial fibrillation (AF). Non‐vitamin K antagonist oral anticoagulants (NOACs) are an alternative to warfarin, but there are limited data to support their use in patients with HCM and AF. We sought to compare thromboembolic events, bleeding, and mortality between NOAC and warfarin in patients with HCM and AF. METHODS: From the Korean National Health Insurance Service database during the period from January 1, 2011, to December 31, 2016, we identified a warfarin‐treated group of patients with HCM and AF (n = 955) who were compared with a 1:2 propensity‐matched NOAC treated group (n = 1,504). RESULTS: After a median follow‐up of 16 months, the incidence rates of ischemic stroke and major bleeding were similar between NOAC‐ and warfarin‐treated patients with HCM and AF. NOAC‐treated patients had lower incidence rates for all‐cause mortality (5.11 and 10.13 events per 100 person‐years for NOAC and warfarin groups) and the composite of fatal cardiovascular events (0.77 and 1.80 events per 100 person‐years). Compared with warfarin, use of NOACs was associated with a significantly lower risk of all cause‐mortality (hazard ratio, 0.43; 95% CI, 0.32‐0.57) and composite fatal cardiovascular events (hazard ratio, 0.39; 95% CI, 0.18‐0.82). CONCLUSIONS: Compared with warfarin, patients with HCM and AF on NOACs had similar stroke and major bleeding risks, but lower all‐cause mortality and composite fatal cardiovascular events. Our data suggest that patients with HCM and AF can be safely and effectively treated with NOACs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.chest.2018.11.009

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 70

Metadata

Authors
Jung, H., Yang, P.-S., Jang, E., Yu, H. T., Kim, T.-H., Uhm, J.-S., Kim, J.-Y., Pak, H.-N., Lee, M.-H., Joung, B., & Lip, G. Y. H.
Venue
Chest
Publisher
Elsevier BV
Published
2019-02
Volume
155
Issue
2
Pages
354-363
ISSN
0012-3692 (ISSN-L)
OpenAlex
W2905880887
Cited by
70
References
4
FWCI
5.51
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation With Hypertrophic Cardiomyopathy. https://app.cochat.ai/papers/10.1016/j.chest.2018.11.009
The paper
Jung, H., Yang, P.-S., Jang, E., Yu, H. T., Kim, T.-H., Uhm, J.-S., Kim, J.-Y., Pak, H.-N., Lee, M.-H., Joung, B., & Lip, G. Y. H. (2019). Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation With Hypertrophic Cardiomyopathy. Chest. https://doi.org/10.1016/j.chest.2018.11.009

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.